*5.1. pCDs Reduce the Toxicity of Some Exogenous Organisms*

The amorphous cavity of pCDs can capture a variety of drugs, thereby adjusting the physical and chemical properties of the guest molecule. Forming highly stable host–guest complexes with pCDs will reduce the biological effects of the guest molecules, and the improved bioavailability would reduce the toxicity of some exogenous organisms [110–113].

Guo et al. [46] prepared an inclusion compound of podophyllotoxin (PPT) and -CD, which could greatly reduce the toxicity of PPT. The behavior, characterization, and water solubility of the inclusion compound were carefully studied using multiple techniques. The inclusion compound was formed with a ratio of 1:1 and had a considerable stability constant K-s (4245.5 Lmol−<sup>1</sup> ). The anti-cancer activity of the inclusion compound was better than that of cisplatin (DDP, positive control). Faisal et al. [114] studied the protective effect of -CD on the toxicity of HeLa cells and zebrafish embryos induced by zelaketone. Under certain conditions, sulfobutyl, methyl, and succinyl substituted CDs formed stable complexes, which significantly reduced or even eliminated the toxicity of azilenone. In addition, cotreatment with -CD also significantly reduced the sublethal effect of zaraketone. Studies have also shown that the formation of a stable zelenone-CD complex can significantly reduce or even eliminate the toxicity of zelenone in vivo and in vitro. Therefore, CD is expected to become a new mycotoxin binder.
